Bio-Path (BPTH) Stock Price, News & Analysis

Company Overview

Bio-Path Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel RNA-based therapies for the treatment of cancer. Leveraging its proprietary nanoscale liposomal DNA/RNA delivery platform, Bio-Path designs molecules that target key cancer-promoting genes and pathways. Its lead programs include BP-1001, an antisense oligonucleotide targeting Grb2 for hematological malignancies, and BP-1002, which inhibits the BCL-2 gene to induce apoptosis in cancer cells. These targeted approaches aim to overcome limitations of conventional chemotherapy by improving drug delivery and reducing off-target effects.

The company’s pipeline is built around its Nano-sugar functionalized liposome delivery system, which enhances cellular uptake and stability of therapeutic oligonucleotides. Bio-Path has advanced multiple candidates into clinical trials for acute myeloid leukemia, myelodysplastic syndrome and solid tumors, including ongoing Phase 1/2 studies. Preclinical work on additional programs, such as BP-1003, explores complementary oncogenic pathways, positioning the company for potential expansion of its product portfolio.

Founded in 2004 and headquartered in Henderson, Nevada, Bio-Path conducts research and development activities at its laboratory facilities in Houston, Texas. The company collaborates with leading cancer centers and contract research organizations across North America and Europe to support its global clinical trial efforts. Its strategic partnerships and academic alliances provide access to advanced translational science and accelerate the path toward regulatory milestones.

Under the leadership of Chief Executive Officer Peter Yanchurov, Bio-Path is guided by a management team with extensive experience in oncology drug development, clinical operations and financing. The company’s board of directors includes industry veterans and scientific experts who oversee strategic decision-making and corporate governance. Bio-Path continues to seek capital and partnering opportunities to support its mission of delivering innovative RNA-based therapies to patients with high-need cancers.

Key Stats

• Today's Range: $0.16 to $0.17
• 50-Day Range: $0.16 to $0.22
• 52-Week Range: $0.12 to $3.39
• Volume: 17,706 shs
• Average Volume: 988,724 shs
• Market Capitalization: $1.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bio-Path Stock Analysis - MarketRank™

Bio-Path scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bio-Path.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bio-Path are expected to grow in the coming year, from ($3.34) to ($1.55) per share.

Price to Book Value per Share Ratio

Bio-Path has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Bio-Path has been sold short.

Short Interest Ratio / Days to Cover

Bio-Path has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Path has recently decreased by 87.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bio-Path does not currently pay a dividend.

Dividend Growth

Bio-Path does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.10% of the float of Bio-Path has been sold short.

Short Interest Ratio / Days to Cover

Bio-Path has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Path has recently decreased by 87.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for BPTH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Bio-Path to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Path insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.72% of the stock of Bio-Path is held by insiders.

Percentage Held by Institutions

Only 5.74% of the stock of Bio-Path is held by institutions.

BPTH Stock Analysis - Frequently Asked Questions

How have BPTH shares performed this year?

Bio-Path's stock was trading at $1.16 at the beginning of the year. Since then, BPTH stock has decreased by 85.5% and is now trading at $0.1680.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its earnings results on Thursday, August, 15th. The company reported ($1.16) EPS for the quarter, topping analysts' consensus estimates of ($1.54) by $0.38.
Read the conference call transcript.

When did Bio-Path's stock split?

Bio-Path's stock reverse split on Friday, February 23rd 2024.The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), Micron Technology (MU), Anavex Life Sciences (AVXL) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 7/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BPTH
• CIK: 1133818
• Web: www.biopathholdings.com
• Phone: (832) 742-1357
• Fax: N/A
• Employees: 10
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,842.40%
• Return on Assets: -337.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.86
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 8,308,000
• Free Float: 5,726,000
• Market Cap: $1.40 million
• Optionable: Optionable
• Beta: -0.03